Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia

• Published in: Vascular health and risk management Vol. 18; pp. 481 - 493
• Main Authors: Gelaye, Abebech Tewabe, Seid, Mohammed Assen, Baffa, Lemlem Daniel
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 31.07.2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: ACE inhibitors; Analysis; Angiotensin; angiotensin-converting enzyme inhibitors; Antihypertensive drugs; Cardiac patients; Chronic illnesses; Clinics; Comorbidity; Data collection; Disease; dose optimization; Drug therapy; Ejection fraction; Ethics; ethiopia; Heart failure; Hospitals; Medical records; Morbidity; Mortality; Optimization; Original Research; Questionnaires; Sociodemographics; Variables; Ethiopia
• ISSN: 1178-2048; 1176-6344; 1178-2048
• DOI: 10.2147/VHRM.S363051

Introduction: Angiotensin-converting enzyme inhibitors dose optimizations (ACEIs) are essential to boost the treatment outcome in heart failure patients (HF) with reduced ejection fraction. Therefore, the main purpose of this study was to evaluate dose optimization and associated factors of ACEIs among HF patients. Method: An institutional-based retrospective study was conducted on 256 study participants from May 20 to August 30, 2020 in ambulatory care clinic at Felege Hiwot Comprehensive Specialized Hospital. A systematic random sampling method was carried out to select study participants. Data were collected from the patient interview and the review of medical records. Epidata and SPSS version 22 were used for data entry and analysis. A bivariate logistic regression analysis was done to determine the association of independent variables with a dose optimization of ACEIs. Results: The mean age of the subjects in the study was 53.82 years with a standard deviation (SD) of 17.067 and more than half of (60.9%) the patients were unable to read and write. Among participants who were receiving ACEIs, only 30.6% were taking an optimal dose. Age [greater than or equal to]65 years (AOR 5.04 (2.81-12.56)) and a dose of furosemide [greater than or equal to]40 mg (AOR, 2.62 (1.28-16.74)) were significantly associated with the suboptimal dose of ACEIs. Conclusion: Only one-third of patients received the optimum dose of ACEIs. Older age and dose of furosemide greater >40 mg were significantly associated with suboptimal dosing of ACEIs. Therefore, more attention must be given to older patients with HF in order to optimize the dose of ACEIs administered. Keywords: ACEIS, dose optimization, HF, Ethiopia